FN2 Earnings Intelligence
McKesson Corporation earnings overview
Latest McKesson Corporation (MCK) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
McKesson Corporation
The quarter supports a constructive operating thesis: specialty demand and technology-led efficiency are contributing to growth, while the raised FY27 outlook improves visibility. The key test is whether these gains persist as pricing, regulation, free cash flow, and separation execution remain constraints.
McKesson Corporation
McKesson closed fiscal 2026 with 18% adjusted EPS growth and $6.2 billion in operating cash flow, but Q4 revenue of $96.3 billion fell short of the $101.3 billion consensus as the North American Pharmaceutical segment lagged estimates. The stock declined 3.3% on an abnormal basis in the session following the report before recovering 4.2% in subsequent trading. Management reaffirmed FY27 EPS guidance of $43.80-$44.60, signaling continued 12-14% earnings growth driven by oncology platform expansion, specialty pharmaceutical distribution, and AI-driven automation. The pending Medical-Surgical Solutions separation, anchored by Apollo Funds' $1.25 billion minority investment for a 13% stake, represents a significant strategic milestone expected to unlock value. The shift from raised guidance in Q3 to maintained guidance in Q4 suggests management views the current trajectory as on track…
McKesson Corporation
The current quarter supports a constructive operating trajectory: growth in oncology, multispecialty services, GLP-1 distribution, and technology-enabled productivity accompanied a higher full-year EPS outlook. The main test is whether margin gains and demand remain durable amid regulatory, seasonal, integration, and pricing risks.
McKesson Corporation
The current analysis supports a constructive near-term operating picture for McKesson: specialty distribution, oncology, GLP-1 demand and technology-enabled services supported strong Q2 results and a higher full-year EPS outlook. The thesis remains dependent on execution against capital investments, acquisition integration and the planned Medical-Surgical separation.
McKesson Corporation
The quarter supports a constructive operating thesis: resilient oncology and specialty demand, service-platform expansion and productivity investment are supporting growth. The thesis remains conditional on acquisition integration, portfolio execution, pricing, reimbursement and GLP-1 and biosimilar dynamics.
McKesson Corporation
The quarter supports a constructive view of McKesson's growth trajectory: specialty pharmaceutical demand, oncology services, prescription technology, and the PRISM Vision expansion were highlighted as growth drivers. The main counterweights are softer medical-surgical demand and execution, regulatory, and policy risks.
McKesson Corporation
The quarter supports a constructive operating narrative: strong U.S. pharmaceutical demand and oncology expansion were accompanied by higher guidance. The case still depends on executing strategic investments and managing volatility in RxTS and Medical-Surgical.
Get the MCK recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.